Table 2.
Pharmacokinetic parameters of PMX and QCN in rats after oral administration of PMX, QCN in 0.3% NaCMC, or PMX/DCK-QCN-NE.
| Test Material | PMX | QCN | |||
|---|---|---|---|---|---|
| PMX in Water | PMX/DCK in Water | PMX/DCK-QCN-NE | QCN in 0.3% NaCMC | PMX/DCK-QCN-NE | |
| Administration | Oral | Oral | Oral | Oral | Oral |
| Dose of PMX or QCN (mg/kg) | 50 | 50 | 50 | 40 | 40 |
| Tmax (h) | 0.833 ± 0.577 | 0.667 ± 0.289 | 4.00 ± 0.000 ***,### | 2.00 ± 0.000 | 1.67 ± 0.289 |
| T1/2 (h) | 6.06 ± 1.83 | 4.10 ± 1.40 | 3.34 ± 0.589 | 4.83 ± 2.68 | 4.76 ± 0.551 |
| Cmax (μg/mL) | 0.452 ± 0.221 | 2.28 ± 1.05 ** | 1.28 ± 0.072 | 0.336 ± 0.122 | 7.38 ± 3.03 $$ |
| AUClast (μg∙h/mL) | 1.39 ± 0.395 | 5.49 ± 1.01 *** | 6.29 ± 0.677 *** | 1.26 ± 0.665 | 30.1 ± 7.57 $$$ |
| AUCinf (μg∙h/mL) | 2.56 ± 0.755 | 6.99 ± 1.63 ** | 9.02 ± 1.38 *** | 2.60 ± 1.03 | 47.6 ± 12.9 $$$ |
| Relative bioavailability | 1.00 | 3.94 ± 0.727 *** | 4.51 ± 0.486 *** | 1.00 | 23.9 ± 6.00 $$$ |
Tmax, time to reach maximum plasma concentration; T1/2, half-life of plasma concentration; Cmax, maximum plasma concentration; AUClast, area under the plasma concentration-time curve from zero to the time of the last measurable plasma concentration; AUCinf, area under the plasma concentration-time curve from zero to infinity; Relative bioavailability, (AUClast, PMX in test material/DosePMX in test material)/(AUClast, PMX in water/DosePMX in water) or (AUClast, QCN in test material/DoseQCN in test material)/(AUClast, QCN in 0.3% NaCMC/DoseQCN in 0.3% NaCMC). Values ar expressed as mean ± standard deviation (n = 4). ** p < 0.01, *** p < 0.001 compared with PMX in water; ### p < 0.001 compared with PMX/DCK; $$$ p < 0.001, $$$ p < 0.001 compared with QCN in 0.3% NaCMC.